Viral Vector and Plasmid DNA Manufacturing Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Product Type (Plasmid DNA, Viral Vector, and Non-viral Vector), Application (Cancer, Genetic Disorder, Infectious Disease, and Other Applications), By Region, and Competition 2018-2028

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

5.49 billion

CAGR (2023-2028)

10.89%

Fastest Growing Segment

Cancer 

Largest Market

North America

Market Overview

Global Viral Vector and Plasmid DNA Manufacturing Market has valued at USD 5.49 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 10.89% through 2028. Viral vector and plasmid DNA manufacturing are essential processes in biotechnology and biopharmaceutical industries, particularly for applications like gene therapy, vaccine production, and genetic engineering. These processes involve the production and purification of viral vectors and plasmid DNA, which serve as crucial tools for various applications in the field of molecular biology and medicine. Different types of viral vectors are used, such as adeno-associated viruses (AAVs), lentiviruses, retroviruses, and others. The choice depends on the specific application and target cells. Plasmid DNA (pDNA) is a circular, double-stranded DNA molecule found in bacteria. It is commonly used in biotechnology for various purposes, including the production of recombinant proteins, gene cloning, and as a vector for gene therapy. A significant driver for the market is the growing investment in gene therapy research and development. Both viral vectors and plasmid DNA are essential components in gene therapy products. The potential to develop novel treatments for genetic and rare diseases has attracted substantial funding from both public and private sectors.

Ongoing advancements in biotechnology, including gene editing techniques like CRISPR-Cas9, have expanded the possibilities for gene therapy. This has driven the need for efficient and safe delivery systems, which viral vectors and plasmid DNA provide. The success of several gene therapies in clinical trials and their subsequent approvals by regulatory agencies, such as the FDA and EMA, have boosted confidence in the field. These successes encourage further investment and development in viral vectors and plasmid DNA. Gene therapies offer the potential for highly targeted treatments, which can minimize side effects and improve patient outcomes. This targeted approach is particularly attractive for cancer treatments and other complex diseases.

Key Market Drivers

Advancements in Biotechnology

Technologies like CRISPR-Cas9 have revolutionized genetic engineering. They allow precise and efficient modification of genes in various organisms, holding tremendous potential for treating genetic diseases, creating genetically modified organisms (GMOs), and advancing basic research. Advances in genomics have made it possible to sequence entire genomes quickly and cost-effectively. This has paved the way for personalized medicine, where treatments are tailored to an individual's genetic makeup, increasing treatment efficacy, and reducing side effects. The biopharmaceutical industry has grown significantly, producing complex drugs like monoclonal antibodies, vaccines, and gene therapies. Biomanufacturing techniques have improved, leading to more efficient and cost-effective production of these drugs. Synthetic biology involves designing and constructing biological parts, devices, and systems to perform specific functions. This field has led to the creation of synthetic organisms, biosensors, and biofuels. Stem cell research has advanced significantly, leading to the development of stem cell therapies for various diseases and injuries. These therapies have the potential to regenerate damaged tissues and organs. Advances in bioinformatics have enabled the efficient storage, analysis, and interpretation of vast amounts of biological data. This is crucial for genomics, drug discovery, and understanding complex biological processes. Biotechnology is being used to address environmental challenges, such as pollution remediation, waste management, and the development of biofuels and bioplastics.

Genetically modified crops (GMOs) have been developed to improve crop yield, resistance to pests and diseases, and nutritional content. This technology has the potential to enhance food security and sustainability. Biotechnology has led to the development of novel vaccines and immunotherapies for infectious diseases and cancer. These treatments harness the body's immune system to combat diseases. The study of the human microbiome has revealed the crucial role of microorganisms in human health. Advances in microbiome research have implications for understanding and treating various diseases. The integration of nanotechnology with biotechnology has led to the development of nanoparticles and nanoscale tools for drug delivery, imaging, and diagnostics. 3D bioprinting technology allows the fabrication of complex tissues and organs using living cells. This has potential applications in regenerative medicine and tissue engineering. Biotechnology is used to develop biosensors and bioremediation techniques for monitoring and cleaning up environmental pollutants. AI and machine learning are increasingly used to analyze biological data, model biological systems, and assist in drug discovery and development. This factor will help in the development of Global Viral Vector and Plasmid DNA Manufacturing Market.

Increasing Investment in Gene Therapy

Gene therapy involves the introduction of therapeutic genes or genetic material into a patient's cells to treat or prevent disease. Viral vectors and plasmid DNA serve as essential tools for delivering these therapeutic genes into target cells. Viral vectors, such as adeno-associated viruses (AAVs) or lentiviruses, are used for in vivo gene therapy, while plasmid DNA is often employed in ex vivo gene therapy. The development of gene therapies starts with extensive research and preclinical studies. This research phase often involves testing different viral vectors and plasmid DNA constructs to optimize delivery and expression of therapeutic genes. Investment in research drives the demand for these materials. Gene therapies must go through rigorous clinical trials to demonstrate safety and efficacy before they can be approved for widespread use. These trials require substantial quantities of viral vectors and plasmid DNA, especially as they progress to larger patient populations. Once a gene therapy is proven effective in clinical trials, it enters the commercialization phase. This involves scaling up production to meet market demand. Viral vectors and plasmid DNA manufacturers play a critical role in providing the necessary materials for large-scale production.

Gene therapy has a wide range of applications beyond rare genetic diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. The versatility of viral vectors and plasmid DNA makes them suitable for various therapeutic areas, further increasing demand. Regulatory agencies like the FDA in the United States have introduced expedited pathways and designations for promising gene therapies. These pathways encourage investment in gene therapy development and manufacturing. Success stories in gene therapy, such as the approval of Luxturna and Zolgensma, have bolstered investor confidence in the field. Increased funding from both venture capital and pharmaceutical companies fuels the development and manufacturing of viral vectors and plasmid DNA. The demand for gene therapies is not limited to a single region. It is a global market, and as more countries recognize the potential of gene therapy, there is a growing need for a reliable supply of viral vectors and plasmid DNA worldwide. Ongoing advancements in bioprocessing and manufacturing techniques for viral vectors and plasmid DNA are making production more efficient and cost-effective, aligning with the needs of a growing market. Gene therapy offers the potential for transformative treatments, which attracts investment and support from patients, advocacy groups, and healthcare systems. This factor will pace up the demand of Global Viral Vector and Plasmid DNA Manufacturing Market.

Technological Advancements

Single-use bioreactors have gained popularity in biopharmaceutical manufacturing, including viral vector and plasmid DNA production. These disposable systems offer flexibility, reduce the risk of contamination, and decrease setup times compared to traditional stainless-steel bioreactors. Advances in cell culture media and bioprocess optimization have led to higher cell densities and productivity. This results in increased yields of viral vectors and plasmid DNA from bioreactors, reducing production costs. The development of stable and high-yielding cell lines for viral vector and plasmid DNA production has led to more efficient and consistent manufacturing processes. Modified cell lines optimized for specific applications can increase productivity. New chromatography and purification techniques have been developed to enhance the purity and yield of viral vectors and plasmid DNA. Improved resin materials, column designs, and purification strategies contribute to higher product quality. Closed and automated systems minimize the risk of contamination, reduce operator intervention, and increase the reproducibility of manufacturing processes. These systems are particularly important in the production of viral vectors and plasmid DNA for clinical applications. Advances in analytical techniques and quality control methods enable real-time monitoring and characterization of viral vector and plasmid DNA products. This ensures product consistency and helps meet regulatory requirements.

Process Analytical Technology (PAT) tools, including sensors and data analytics, are integrated into manufacturing processes to provide real-time data and enable process control and optimization. This enhances product quality and reduces the need for time-consuming offline testing. Scalable manufacturing platforms are crucial to meet the increasing demand for viral vectors and plasmid DNA. Modular and flexible systems allow for easy scale-up from research and development to commercial production. New platforms and technologies for viral vector production, such as baculovirus-insect cell systems and transient transfection using suspension-adapted cell lines, offer alternatives to traditional adherent cell culture methods. Continuous manufacturing approaches are being explored to replace batch processes in viral vector and plasmid DNA production.

Continuous systems offer greater productivity, reduced production time, and smaller facility footprints. Enhanced safety measures, such as containment systems and viral inactivation technologies, have been developed to mitigate the risks associated with handling viral vectors, especially when working with pathogenic viruses. Overall cost reduction strategies, including more efficient use of resources, optimization of raw materials, and improved process yields, contribute to the affordability and accessibility of viral vectors and plasmid DNA products. Manufacturers are increasingly focused on sustainability, exploring eco-friendly materials and processes to reduce the environmental impact of viral vector and plasmid DNA production. This factor will accelerate the demand of Global Viral Vector and Plasmid DNA Manufacturing Market.


Download Free Sample Report

Key Market Challenges

Costs and Pricing Pressures

Viral vector and plasmid DNA manufacturing processes can be complex, involving multiple steps and the use of specialized equipment and materials. These processes can be costly to establish and operate, leading to higher production costs. As gene therapies progress from research and development to commercial production, companies face the challenge of scaling up manufacturing processes. Achieving economies of scale while maintaining product quality is a delicate balance that impacts costs. Meeting stringent regulatory requirements for gene therapy products adds additional costs to manufacturing. Companies must invest in quality control, documentation, and compliance measures, which can be resource intensive. Ensuring the safety and efficacy of viral vectors and plasmid DNA products requires rigorous quality control and assurance processes. These processes can increase production costs, especially when addressing deviations or maintaining consistent quality. Building and maintaining state-of-the-art manufacturing facilities and cleanrooms compliant with Good Manufacturing Practices (GMP) standards is a significant upfront investment that can lead to cost pressures. The cost of raw materials, such as cell culture media, growth factors, and purification reagents, can impact overall manufacturing costs. Supply chain disruptions or fluctuations in raw material prices can increase these costs. Proper disposal of waste materials generated during manufacturing, including biological waste and hazardous materials, can be expensive and regulated.

Ethical and Societal Considerations

The ability to modify genes raises concerns about the potential for genetic enhancement and the creation of designer babies. Ethical debates revolve around the boundaries of gene editing and the implications for future generations. Ensuring that patients fully understand the risks and benefits of gene therapy is crucial. Obtaining informed consent from patients and, in some cases, their families or guardians, can be challenging, especially when dealing with vulnerable populations. There are concerns about equitable access to gene therapies. High costs can limit access to these treatments, potentially exacerbating health disparities. Ensuring affordability and accessibility for all patients is an ethical imperative. Gene therapies are relatively new, and their long-term safety and efficacy are not always well-understood.

Ethical considerations include the need for ongoing monitoring and the obligation to report adverse events. Editing the germline (sperm and egg cells) raises significant ethical questions. Permanent genetic changes made to the germline can be passed on to future generations, potentially altering the human gene pool. Obtaining informed consent for germline editing is particularly complex, as the implications extend to descendants who cannot provide consent. Global discussions are ongoing to establish guidelines and regulations for such interventions. Gene editing techniques can sometimes have unintended "off-target" effects, potentially causing harm. Ethical considerations include the need to minimize off-target effects and disclose any risks to patients.

Key Market Trends

Cell and Gene Therapy Ecosystem Development

Collaboration among academic institutions, research organizations, and biopharmaceutical companies is crucial for advancing cell and gene therapy technologies. These partnerships enable the exchange of knowledge, expertise, and resources, accelerating the development of innovative therapies. Many countries have established specialized research centers and institutes dedicated to cell and gene therapy research. These centers serve as hubs for cutting-edge research and provide a nurturing environment for scientists and innovators. Biotechnology clusters or hubs, often located in regions with a strong biotech presence, foster innovation, collaboration, and investment in cell and gene therapy. Examples include the Boston-Cambridge area in the United States and the Golden Triangle in the United Kingdom. Governments and private entities are providing funding and grants to support cell and gene therapy research and development.

These initiatives help attract top talent and stimulate innovation in the field. Regulatory agencies are actively engaged in shaping policies and pathways for cell and gene therapies. They provide guidance, expedited review processes, and incentives to facilitate product development and approvals. Investments in manufacturing facilities and infrastructure that meet Good Manufacturing Practices (GMP) standards are essential. This includes the construction of specialized cell and gene therapy manufacturing plants. Patient advocacy organizations and support groups play a vital role in advancing cell and gene therapies. They raise awareness, advocate for patients' needs, and provide valuable insights to researchers and developers. Venture capital firms and investors are increasingly interested in funding cell and gene therapy startups. This investment activity drives innovation and entrepreneurship in the ecosystem.

Segmental Insights

Product Type Insights

In 2022, the Global Viral Vector and Plasmid DNA Manufacturing Market largest share was held by Plasmid DNA segment and is predicted to continue expanding over the coming years.  Plasmid DNA is used in various applications beyond gene therapy, including vaccine development, protein expression, and research purposes. This versatility allows it to have a broader market reach and more diverse customer base compared to viral vectors, which are primarily used in gene therapy. Plasmid DNA plays a crucial role in the development of DNA-based vaccines, which have gained attention due to their potential in preventing infectious diseases. The COVID-19 pandemic led to increased demand for DNA vaccines, boosting the plasmid DNA manufacturing market. Many biopharmaceutical and biotech companies already have established infrastructure and expertise for plasmid DNA production, making it a convenient choice for in-house research and development.

Application Insights

In 2022, the Global Viral Vector and Plasmid DNA Manufacturing Market cancer segment to witness robust growth in the forecast period and is predicted to continue expanding over the coming years. Cancer remains a leading cause of mortality worldwide, and there is a substantial unmet medical need for more effective treatments. Gene therapy, including the use of viral vectors and plasmid DNA, holds promise as a novel approach to targeting and treating various types of cancer. Ongoing research in oncology has led to a deeper understanding of the genetic and molecular basis of cancer. This knowledge has paved the way for the development of gene therapies that can target specific genetic mutations and pathways responsible for cancer growth. Gene therapies can be designed to target cancer cells specifically, minimizing damage to healthy tissues and reducing side effects compared to traditional chemotherapy and radiation therapy. This targeted approach is particularly attractive for treating cancer.


Download Free Sample Report

Regional Insights

The North America region dominates the Global Viral Vector and Plasmid DNA Manufacturing Market in 2022. North America, particularly the United States, has a well-developed and mature biopharmaceutical industry. The region is home to numerous biotechnology and pharmaceutical companies with extensive experience in research, development, and manufacturing of biologics, including viral vectors and plasmid DNA. North America has been at the forefront of gene therapy research and development. The United States has seen significant investment and progress in the field, leading to a higher number of clinical trials and commercialization efforts involving viral vectors and plasmid DNA. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) have provided clear pathways and guidance for the development and approval of gene therapies. This regulatory clarity has attracted investments and encouraged companies to pursue clinical development and manufacturing activities in the region.

Recent Developments

  • In July 2021, to address the rapidly expanding need for plasmid DNA-based medicines and essential mRNA-based vaccinations, Thermo Fisher Scientific Inc., the industry leader in providing science services, launched a new cGMP plasmid DNA production facility in Carlsbad, California. Plasmid DNA is being utilized more frequently in gene treatments and some vaccines as a therapeutic component. Because of its benefits, such as weak immunogenicity, greater safety, and ease of fabrication, demand for materials and manufacturing capacity has skyrocketed worldwide.
  • In March 2021, Genopis Inc., the San Diego, California-based producer of plasmid DNA that Wacker purchased in February, has changed its name to Wacker Biotech US Inc. A connected business and a plasmid DNA (pDNA) CDMO site are the subject of the acquisition. Wacker Biotech US Inc. enhances Wacker's current portfolio by offering expertise in pDNA technology and lays the groundwork for future expansion in the biopharma industry. Wacker Biotech US Inc. also gives Wacker a local foothold in the biopharmaceuticals sector in the United States.
  • In June 2020, A major supplier of goods and services to the biotechnology sector, Aldevron, recently announced a collaboration with Ziopharm Oncology to create plasmid DNA for T cell treatment of solid tumours. To serve this emerging and quickly expanding industry, Aldevron has created the neoGMP service level. According to the agreement, Ziopharm will discover TCRs for each patient individually and compile TCRs into a library for use in clinical trials based on their studies of patient tumours. The business will quickly and affordably produce many DNA plasmids using Aldevron's neoGMP service. Aldevron produces nucleic acids, proteins, and antibodies on demand for the biotechnology sector.  To cure the millions of patients worldwide who are diagnosed with a solid tumour each year, Ziopharm is creating non-viral, cytokine-driven cell and gene therapies that weaponize the body's immune system. Ziopharm is at the forefront of immuno-oncology with its multiplatform strategy and aims to treat any kind of solid tumour. Based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and quickly manufactured Sleeping Beauty-enabled CD19-specific CAR-T programme, Ziopharm's pipeline is designed for commercially scalable, cost-effective T cell receptor T cell therapeutics.

Key Market Players

  • Oxford Biomedica PLC
  • Cognate BioServices Inc.
  • Cell and Gene Therapy Catapult Ltd.
  • FinVector Vision Therapies
  • Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)
  • SIRION Biotech GmbH
  • Merck KGaA Inc.
  • Thermo Fisher Scientific
  • Uniqure NV
  • Catalent Inc.

By Product Type

By Application

By Region
  • Plasmid DNA
  • Viral Vector
  • Non-viral Vector
  • Cancer
  • Genetic Disorder
  • Infectious Disease
  • Other Applications
  • North America
  • Asia-Pacific
  • Europe
  • South America
  • Middle East & Africa


Report Scope:

In this report, the Global Viral Vector and Plasmid DNA Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  •  Viral Vector and Plasmid DNA Manufacturing Market, By Product Type:

o   Plasmid DNA

o   Viral Vector

o   Non-viral Vector

  •  Viral Vector and Plasmid DNA Manufacturing Market, By Application:

o   Cancer

o   Genetic Disorder

o   Infectious Disease

o   Other Applications

  • Global Viral Vector and Plasmid DNA Manufacturing Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Viral Vector and Plasmid DNA Manufacturing Market.

Available Customizations:

Global Viral Vector and Plasmid DNA Manufacturing Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Viral Vector and Plasmid DNA Manufacturing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.   Markets Covered

1.2.2.   Years Considered for Study

1.2.3.   Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Viral Vector and Plasmid DNA Manufacturing Market Outlook

5.1.  Market Size & Forecast

5.1.1.         By Value

5.2.  Market Share & Forecast

5.2.1.         By Product Type (Plasmid DNA, Viral Vector, and Non-viral Vector)

5.2.2.         By Application (Cancer, Genetic Disorder, Infectious Disease, and Other Applications)

5.2.3.         By Region

5.2.4.         By Company (2022)

5.3.  Market Map

6.    Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Outlook

6.1.  Market Size & Forecast

6.1.1.         By Value

6.2.  Market Share & Forecast

6.2.1.         By Product Type

6.2.2.         By Application

6.2.3.         By Country

6.3.  Asia Pacific: Country Analysis

6.3.1.         China Viral Vector and Plasmid DNA Manufacturing Market Outlook

6.3.1.1.         Market Size & Forecast

6.3.1.1.1.             By Value

6.3.1.2.         Market Share & Forecast

6.3.1.2.1.             By Product Type

6.3.1.2.2.             By Application

6.3.2.         India Viral Vector and Plasmid DNA Manufacturing Market Outlook

6.3.2.1.         Market Size & Forecast

6.3.2.1.1.             By Value

6.3.2.2.         Market Share & Forecast

6.3.2.2.1.             By Product Type

6.3.2.2.2.             By Application

6.3.3.         Australia Viral Vector and Plasmid DNA Manufacturing Market Outlook

6.3.3.1.         Market Size & Forecast

6.3.3.1.1.             By Value

6.3.3.2.         Market Share & Forecast

6.3.3.2.1.             By Product Type

6.3.3.2.2.             By Application

6.3.4.         Japan Viral Vector and Plasmid DNA Manufacturing Market Outlook

6.3.4.1.         Market Size & Forecast

6.3.4.1.1.             By Value

6.3.4.2.         Market Share & Forecast

6.3.4.2.1.             By Product Type

6.3.4.2.2.             By Application

6.3.5.         South Korea Viral Vector and Plasmid DNA Manufacturing Market Outlook

6.3.5.1.         Market Size & Forecast

6.3.5.1.1.             By Value

6.3.5.2.         Market Share & Forecast

6.3.5.2.1.             By Product Type

6.3.5.2.2.             By Application

7.    Europe Viral Vector and Plasmid DNA Manufacturing Market Outlook

7.1.  Market Size & Forecast

7.1.1.         By Value

7.2.  Market Share & Forecast

7.2.1.         By Product Type

7.2.2.         By Application

7.2.3.         By Country

7.3.  Europe: Country Analysis

7.3.1.         France Viral Vector and Plasmid DNA Manufacturing Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Product Type

7.3.1.2.2.             By Application

7.3.2.         Germany Viral Vector and Plasmid DNA Manufacturing Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Product Type

7.3.2.2.2.             By Application

7.3.3.         Spain Viral Vector and Plasmid DNA Manufacturing Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Product Type

7.3.3.2.2.             By Application

7.3.4.         Italy Viral Vector and Plasmid DNA Manufacturing Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Product Type

7.3.4.2.2.             By Application

7.3.5.         United Kingdom Viral Vector and Plasmid DNA Manufacturing Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Product Type

7.3.5.2.2.             By Application

8.    North America Viral Vector and Plasmid DNA Manufacturing Market Outlook

8.1.  Market Size & Forecast

8.1.1.         By Value

8.2.  Market Share & Forecast

8.2.1.         By Product Type

8.2.2.         By Application

8.2.3.         By Country

8.3.  North America: Country Analysis

8.3.1.         United States Viral Vector and Plasmid DNA Manufacturing Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Product Type

8.3.1.2.2.             By Application

8.3.2.         Mexico Viral Vector and Plasmid DNA Manufacturing Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Product Type

8.3.2.2.2.             By Application

8.3.3.         Canada Viral Vector and Plasmid DNA Manufacturing Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Product Type

8.3.3.2.2.             By Application

9.    South America Viral Vector and Plasmid DNA Manufacturing Market Outlook

9.1.  Market Size & Forecast

9.1.1.         By Value

9.2.  Market Share & Forecast

9.2.1.         By Product Type

9.2.2.         By Application

9.2.3.         By Country

9.3.  South America: Country Analysis

9.3.1.         Brazil Viral Vector and Plasmid DNA Manufacturing Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Product Type

9.3.1.2.2.             By Application

9.3.2.         Argentina Viral Vector and Plasmid DNA Manufacturing Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Product Type

9.3.2.2.2.             By Application

9.3.3.         Colombia Viral Vector and Plasmid DNA Manufacturing Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Product Type

9.3.3.2.2.             By Application

10.  Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market Outlook

10.1.              Market Size & Forecast

10.1.1.      By Value

10.2.              Market Share & Forecast

10.2.1.      By Product Type

10.2.2.      By Application

10.2.3.      By Country

10.3.              MEA: Country Analysis

10.3.1.      South Africa Viral Vector and Plasmid DNA Manufacturing Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Product Type

10.3.1.2.2.           By Application

10.3.2.      Saudi Arabia Viral Vector and Plasmid DNA Manufacturing Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Product Type

10.3.2.2.2.           By Application

10.3.3.      UAE Viral Vector and Plasmid DNA Manufacturing Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Product Type

10.3.3.2.2.           By Application

11.  Market Dynamics

11.1.              Drivers

11.2.              Challenges

12.  Market Trends & Developments

12.1.              Recent Developments

12.2.              Product Launches

12.3.              Mergers & Acquisitions

13.  Global Viral Vector and Plasmid DNA Manufacturing Market: SWOT Analysis

14.  Porter’s Five Forces Analysis

14.1.              Competition in the Industry

14.2.              Potential of New Entrants

14.3.              Power of Suppliers

14.4.              Power of Customers

14.5.              Threat of Substitute Product

15.  PESTLE Analysis

16.  Competitive Landscape

16.1.    Oxford Biomedica PLC

16.1.1.      Business Overview

16.1.2.      Company Snapshot

16.1.3.      Products & Services

16.1.4.      Financials (In case of listed companies)

16.1.5.      Recent Developments

16.1.6.      SWOT Analysis

16.2.    Cognate BioServices Inc.

16.2.1.      Business Overview

16.2.2.      Company Snapshot

16.2.3.      Products & Services

16.2.4.      Financials (In case of listed companies)

16.2.5.      Recent Developments

16.2.6.      SWOT Analysis

16.3.    Cell and Gene Therapy Catapult Ltd.

16.3.1.      Business Overview

16.3.2.      Company Snapshot

16.3.3.      Products & Services

16.3.4.      Financials (In case of listed companies)

16.3.5.      Recent Developments

16.3.6.      SWOT Analysis

16.4.    FinVector Vision Therapies

16.4.1.      Business Overview

16.4.2.      Company Snapshot

16.4.3.      Products & Services

16.4.4.      Financials (In case of listed companies)

16.4.5.      Recent Developments

16.4.6.      SWOT Analysis

16.5.    Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)

16.5.1.      Business Overview

16.5.2.      Company Snapshot

16.5.3.      Products & Services

16.5.4.      Financials (In case of listed companies)

16.5.5.      Recent Developments

16.5.6.      SWOT Analysis

16.6.    SIRION Biotech GmbH

16.6.1.      Business Overview

16.6.2.      Company Snapshot

16.6.3.      Products & Services

16.6.4.      Financials (In case of listed companies)

16.6.5.      Recent Developments

16.6.6.      SWOT Analysis

16.7.    Merck KGaA Inc.

16.7.1.      Business Overview

16.7.2.      Company Snapshot

16.7.3.      Products & Services

16.7.4.      Financials (In case of listed companies)

16.7.5.      Recent Developments

16.7.6.      SWOT Analysis

16.8.    Thermo Fisher Scientific Inc.

16.8.1.      Business Overview

16.8.2.      Company Snapshot

16.8.3.      Products & Services

16.8.4.      Financials (In case of listed companies)

16.8.5.      Recent Developments

16.8.6.      SWOT Analysis

16.9.    Uniqure NV

16.9.1.      Business Overview

16.9.2.      Company Snapshot

16.9.3.      Products & Services

16.9.4.      Financials (In case of listed companies)

16.9.5.      Recent Developments

16.9.6.      SWOT Analysis

16.10.  Catalent Inc.

16.10.1.    Business Overview

16.10.2.    Company Snapshot

16.10.3.    Products & Services

16.10.4.    Financials (In case of listed companies)

16.10.5.    Recent Developments

16.10.6.    SWOT Analysis

17.  Strategic Recommendations

18. About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Viral Vector and Plasmid DNA Manufacturing Market was estimated to be USD 4.70 billion in 2022.

down-arrow

Thermo Fisher Scientific, Uniqure NV, Catalent Inc are some of the key players operating in the Global Viral Vector and Plasmid DNA Manufacturing Market.

down-arrow

Access to gene therapies remains a challenge due to their high costs.

down-arrow

A growing number of gene therapy candidates have been entering clinical trials.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Global Viral Vector and Plasmid DNA Manufacturing Market to grow with a CAGR of 15.30%

Nov, 2023

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Viral Vector and Plasmid DNA Manufacturing Market.

Why Choose Us